Impact of l-Arginine Metabolism on Immune Response and Anticancer Immunotherapy

The progression from neoplastic initiation to malignancy happens in part because of the failure of immune surveillance. Cancer cells successfully escape immune recognition and elimination and create an immune-suppressive microenvironment. A suppressive metabolic microenvironment may also contribute to ineffective T-cell function. Tumor progression is characterized by a complex network of interactions among different cell types that cooperatively exploit metabolic reprogramming. As we start to recognize that cancer cells use different metabolism processes than normal cells do, a better understanding of the functional mechanisms of the regulation and reprogramming of the metabolic landscape in cancer cells is crucial to successful immunotherapy strategies. However, the exact role of metabolism in T cells and in the tumor microenvironment is not known. One pathway that plays an important role in the regulation of immune cell reactivity is arginine metabolism, which has complex cellular functions. l-arginine and its downstream metabolites (e.g., ornithine and citrulline) could be essential to T-cell activation and thus modulate innate and adaptive immunity to further promote tumor survival and growth. Identifying metabolic targets that mediate immunosuppression and are fundamental to sustaining tumor growth is key to increasing the efficacy of immunotherapies.

[1]  Hannah C. Beird,et al.  Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma , 2017, npj Genomic Medicine.

[2]  D. Gabrilovich,et al.  Dendritic cells in cancer: the role revisited. , 2017, Current opinion in immunology.

[3]  J. Roszik,et al.  Targeting iNOS to increase efficacy of immunotherapies , 2017, Human vaccines & immunotherapeutics.

[4]  D. Curiel,et al.  COX2/mPGES1/PGE2 pathway regulates PD-L1 expression in tumor-associated macrophages and myeloid-derived suppressor cells , 2017, Proceedings of the National Academy of Sciences.

[5]  M. Mann,et al.  L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity , 2016, Cell.

[6]  J. Sosman,et al.  Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma , 2016, Cell.

[7]  M. Davies,et al.  Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma , 2016, Clinical Cancer Research.

[8]  P. Thevenot,et al.  l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells. , 2015, Cancer research.

[9]  N. Tan,et al.  Melanoma-initiating cells exploit M2 macrophage TGFβ and arginase pathway for survival and proliferation , 2014, Oncotarget.

[10]  A. Popolo,et al.  l-Arginine and its metabolites in kidney and cardiovascular disease , 2014, Amino Acids.

[11]  S. Ambs,et al.  Tumor microenvironment-based feed-forward regulation of NOS2 in breast cancer progression , 2014, Proceedings of the National Academy of Sciences.

[12]  W. Fast,et al.  Developing an Irreversible Inhibitor of Human DDAH‐1, an Enzyme Upregulated in Melanoma , 2014, ChemMedChem.

[13]  A. Sikora,et al.  Molecular pathways: inflammation-associated nitric-oxide production as a cancer-supporting redox mechanism and a potential therapeutic target. , 2013, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  C. Lindermayr,et al.  Erratum: Nitric oxide-based protein modification: formation and site-specificity of protein S-nitrosylation , 2013, Front. Plant Sci..

[15]  C. Lindermayr,et al.  Nitric oxide-based protein modification: formation and site-specificity of protein S-nitrosylation , 2013, Front. Plant Sci..

[16]  Jung-ki Yoon,et al.  Arginine deprivation therapy for malignant melanoma , 2012, Clinical pharmacology : advances and applications.

[17]  A. Rossary,et al.  Altered functions of natural killer cells in response to L-Arginine availability. , 2012, Cellular immunology.

[18]  K. Tanese,et al.  The role of melanoma tumor‐derived nitric oxide in the tumor inflammatory microenvironment: Its impact on the chemokine expression profile, including suppression of CXCL10 , 2012, International journal of cancer.

[19]  U. Förstermann,et al.  Nitric oxide synthases: regulation and function. , 2012, European heart journal.

[20]  Asif Ali,et al.  Biochemistry of Nitric Oxide , 2011, Indian Journal of Clinical Biochemistry.

[21]  R. Mikkelsen,et al.  Protein tyrosine nitration in cellular signal transduction pathways , 2010, Journal of receptor and signal transduction research.

[22]  R. Medzhitov Inflammation 2010: New Adventures of an Old Flame , 2010, Cell.

[23]  P. Allen,et al.  Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. , 2009, Cancer research.

[24]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[25]  D. Mougiakakos,et al.  Prognostic significance of tumor iNOS and COX-2 in stage III malignant cutaneous melanoma , 2009, Cancer Immunology, Immunotherapy.

[26]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[27]  M. Wangpaichitr,et al.  Arginine deprivation as a targeted therapy for cancer. , 2008, Current pharmaceutical design.

[28]  D. Quiceno,et al.  L-arginine availability regulates T-lymphocyte cell-cycle progression. , 2007, Blood.

[29]  L. Broemeling,et al.  Tumor iNOS predicts poor survival for stage III melanoma patients , 2006, International journal of cancer.

[30]  D. S. Lind,et al.  Arginine and cancer. , 2004, The Journal of nutrition.

[31]  A. Barilli,et al.  The stimulation of arginine transport by TNFα in human endothelial cells depends on NF-κB activation , 2004 .

[32]  M. Hatzoglou,et al.  Regulation of cationic amino acid transport: the story of the CAT-1 transporter. , 2004, Annual review of nutrition.

[33]  E. Grimm,et al.  Depletion of Endogenous Nitric Oxide Enhances Cisplatin-induced Apoptosis in a p53-dependent Manner in Melanoma Cell Lines* , 2004, Journal of Biological Chemistry.

[34]  A. Barilli,et al.  The stimulation of arginine transport by TNFalpha in human endothelial cells depends on NF-kappaB activation. , 2004, Biochimica et biophysica acta.

[35]  J. Cunningham,et al.  Cytokines and Insulin Induce Cationic Amino Acid Transporter (CAT) Expression in Cardiac Myocytes , 1996, The Journal of Biological Chemistry.